MedTrace Logo

Effect of Tegoprazan on Pharmacodynamics of Clopidogrel in Healthy Male Participants

NCT03814642 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2019-10-21

No results posted yet for this study

Summary

This study aims to evaluate the influence of tegoprazan on the pharmacodynamics of clopidogrel according to CYP2C19 genotypes following co-administration of tegoprazan and clopidogrel in healthy male volunteers.

Conditions

  • Healthy

Interventions

DRUG

Clopidogrel 75 mg

Clopidogrel 75 mg tablet

DRUG

Tegoprazan 50 mg

Tegoprazan 50 mg tablet

DRUG

Esomeprazole 20 mg

Esomeprazole 20 mg tablet

Sponsors & Collaborators

  • HK inno.N Corporation

    lead INDUSTRY

Principal Investigators

  • In-Jin Jang · Seoul National University Hospital, Dept. of Clinical Pharmacology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-01-21
Primary Completion
2019-07-22
Completion
2019-07-22

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03814642 on ClinicalTrials.gov